Behavioral Disorders Drug Development Pipeline Review 2017 - Key Players Involved in Therapeutic Development for Autism, OCD and ADHD
Behavioral Disorders Drug Development Pipeline Review 2017 - Key Players Involved in Therapeutic Development for Autism, OCD and ADHD
DUBLIN, March 29, 2018 /PRNewswire/ --
The "Behavioral Disorders Drug Development Pipeline Review, 2017" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The report provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.
Autism, also known as Complex Developmental Disability: There are a total of 41 products in development for this indication, by 34 companies and 4 academic institutions. Key companies operating in this pipeline space include Addex Therapeutics, Confluence Pharmaceuticals and Immuron.
Obsessive-compulsive Disorder (OCD): There are a total of 8 products in development for this indication by 7 companies. Key companies operating in this pipeline space include Addex Therapeutics, Abbvie, Omeros and Phytecs.
Attention Deficit Hyperactivity Disorder (ADHD): There are a total of 58 products in development for this indication, by 41 companies and 5 academic institutions. Key companies operating in this pipeline space include NLS Pharma, Aevi Genomic Medicine, Shire and Highland Therapeutics.
Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G protein-coupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.
Scope
-- Which companies are the most active within the pipeline for behavioral
disorder therapeutics?
-- Which pharmaceutical approaches are the most prominent at each stage of
the pipeline and within each indication?
-- To what extent do universities and institutions play a role within this
pipeline, compared to pharmaceutical companies?
-- What are the most important R&D milestones and data publications to have
happened in the field of behavioral disorders?
Reasons to Buy
-- Understand the overall pipeline, with an at-a-glance overview of all
products in therapeutic development for each indication
-- Assess the products in development in granular detail, with an
up-to-date overview of each individual pipeline program in each
indication, and a comprehensive picture of recent updates and milestones
for each
-- Analyze the companies, institutions and universities currently operating
in the pipeline, and the products being fielded by each of these
-- Understand the composition of the pipeline in terms of molecule type,
molecular target, mechanism of action and route of administration.
Key Topics Covered
1 Table of Contents
2 Introduction
2.1 Behavioral Disorders Report Coverage
2.2 Autism - Overview
2.3 Obsessive-Compulsive Disorder - Overview
2.4 Attention Deficit Hyperactivity Disorder (ADHD) - Overview
3 Therapeutics Development
3.1 Autism
3.2 Obsessive-Compulsive Disorder
3.3 Attention Deficit Hyperactivity Disorder (ADHD)
4 Therapeutics Assessment
4.1 Autism
4.2 Obsessive-Compulsive Disorder
4.3 Attention Deficit Hyperactivity Disorder (ADHD)
5 Companies Involved in Therapeutics Development
5.1 Autism
5.2 Obsessive-Compulsive Disorder
5.3 Attention Deficit Hyperactivity Disorder (ADHD)
6 Dormant Projects
6.1 Autism
6.2 Obsessive-Compulsive Disorder
6.3 Attention Deficit Hyperactivity Disorder (ADHD)
7 Discontinued Products
7.1 Autism
7.2 Obsessive-Compulsive Disorder
7.3 Attention Deficit Hyperactivity Disorder (ADHD)
8 Product Development Milestones
8.1 Autism
8.2 Obsessive-Compulsive Disorder
8.3 Attention Deficit Hyperactivity Disorder (ADHD)
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
Companies Mentioned
-- 4D Pharma PLC
-- 4P-Pharma SAS
-- APeT Holding BV
-- AbbVie Inc
-- Addex Therapeutics Ltd
-- Aequus Pharmaceuticals Inc
-- Aevi Genomic Medicine Inc
-- AgeneBio Inc
-- Alcobra Ltd
-- Amarantus Bioscience Holdings Inc
-- Amorsa Therapeutics Inc
-- Anima Biotech Ltd
-- BCWorld Pharm Co Ltd
-- BioCrea GmbH
-- BioHealthonomics Inc
-- BrainStorm Cell Therapeutics Inc
-- Cingulate Therapeutics LLC
-- Collegium Pharmaceutical Inc
-- Confluence Pharmaceuticals LLC
-- Coronis NeuroSciences Ltd
-- Curemark LLC
-- DRI Biosciences Corp
-- DURECT Corp
-- Eli Lilly and Company
-- F. Hoffmann-La Roche Ltd
-- GW Pharmaceuticals Plc
-- H. Lundbeck A/S
-- Heptares Therapeutics Ltd
-- Highland Therapeutics Inc
-- Immuron Ltd
-- Intra-Cellular Therapies Inc
-- KemPharm Inc
-- Leading BioSciences Inc
-- Luc Therapeutics Inc
-- MedDay SA
-- Merck & Co Inc
-- Neos Therapeutics Inc
-- NeuroDerm Ltd
-- Novartis AG
-- Noven Pharmaceuticals Inc
-- Omeros Corp
-- OptiNose US Inc
-- Otsuka Pharmaceutical Co Ltd
-- Ovensa Inc
-- P2D Bioscience
-- Q BioMed Inc
-- Reviva Pharmaceuticals Inc
-- SK Biopharmaceuticals Co Ltd
-- Shire Plc
-- Sumitomo Dainippon Pharma Co Ltd
-- Sunovion Pharmaceuticals Inc
-- Supernus Pharmaceuticals Inc
-- Taisho Pharmaceutical Holdings Co Ltd
-- Tris Pharma Inc
For more information about this report visit https://www.researchandmarkets.com/research/qtj9mx/behavioral?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/behavioral-disorders-drug-development-pipeline-review-2017---key-players-involved-in-therapeutic-development-for-autism-ocd-and-adhd-300621880.html
SOURCE Research and Markets
